Saravanabavan, N.; Shanmuganathan, P.; Kumarappan, M. Bedaquiline: A Mini Review. Ann SBV., 2020, 8(1), 2-4.
[http://dx.doi.org/10.5005/jp-journals-10085-8101]

Corbett, E.L.; Watt, C.J.; Walker, N.; Maher, D.; Williams, B.G.; Raviglione, M.C.; Dye, C. The growing burden of tuberculosis: Global trends and interactions with the HIV epidemic. Arch. Intern. Med., 2003, 163(9), 1009-1021.
[http://dx.doi.org/10.1001/archinte.163.9.1009] [PMID: 12742798]

Rodriguez-Takeuchi, S.Y.; Renjifo, M.E.; Medina, F.J. Extrapulmonary tuberculosis: Pathophysiology and imaging findings. Radiographics, 2019, 39(7), 2023-2037.
[http://dx.doi.org/10.1148/rg.2019190109] [PMID: 31697616]

Lange, C.; Chesov, D.; Heyckendorf, J.; Leung, C.C.; Udwadia, Z.; Dheda, K. Drug-resistant tuberculosis: An update on disease burden, diagnosis and treatment. Respirology, 2018, 23(7), 656-673.
[http://dx.doi.org/10.1111/resp.13304] [PMID: 29641838]

Nguyen, L. Antibiotic resistance mechanisms in M. tuberculosis: An update. Arch. Toxicol., 2016, 90(7), 1585-1604.
[http://dx.doi.org/10.1007/s00204-016-1727-6] [PMID: 27161440]

Sandhu, G.K. Tuberculosis: Current situation, challenges and overview of its control programs in India. J. Glob. Infect. Dis., 2011, 3(2), 143-150.
[http://dx.doi.org/10.4103/0974-777X.81691] [PMID: 21731301]

WHO G.. Global tuberculosis report 2020. Glob. Tuberc. Rep., 2020.

Chakaya, J.; Khan, M.; Ntoumi, F.; Aklillu, E.; Fatima, R.; Mwaba, P.; Kapata, N.; Mfinanga, S.; Hasnain, S.E.; Katoto, P.D.; Bulabula, A.N. Global tuberculosis report 2020-reflections on the global tb burden, treatment and prevention efforts; IJID, 2020.

Basaraba, R.J. Experimental tuberculosis: The role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.), 2008, 88(Suppl. 1), S35-S47.
[http://dx.doi.org/10.1016/S1472-9792(08)70035-0] [PMID: 18762152]

Wong, E.B.; Cohen, K.A.; Bishai, W.R. Rising to the challenge: New therapies for tuberculosis. Trends Microbiol., 2013, 21(9), 493-501.
[http://dx.doi.org/10.1016/j.tim.2013.05.002] [PMID: 23764389]

Andries, K.; Verhasselt, P.; Guillemont, J.; Göhlmann, H.W.; Neefs, J.M.; Winkler, H.; Van Gestel, J.; Timmerman, P.; Zhu, M.; Lee, E.; Williams, P.; de Chaffoy, D.; Huitric, E.; Hoffner, S.; Cambau, E.; Truffot-Pernot, C.; Lounis, N.; Jarlier, V. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005, 307(5707), 223-227.
[http://dx.doi.org/10.1126/science.1106753] [PMID: 15591164]

Lakshmanan, M.; Xavier, A.S. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. J. Young Pharm., 2013, 5(4), 112-115.
[http://dx.doi.org/10.1016/j.jyp.2013.12.002] [PMID: 24563587]

Koul, A.; Dendouga, N.; Vergauwen, K.; Molenberghs, B.; Vranckx, L.; Willebrords, R.; Ristic, Z.; Lill, H.; Dorange, I.; Guillemont, J.; Bald, D.; Andries, K. Diarylquinolines target subunit c of mycobacterial ATP synthase. Nat. Chem. Biol., 2007, 3(6), 323-324.
[http://dx.doi.org/10.1038/nchembio884] [PMID: 17496888]

Biuković G.; Basak, S.; Manimekalai, M.S.; Rishikesan, S.; Roessle, M.; Dick, T.; Rao, S.P.; Hunke, C.; Grüber, G. Variations of subunit varepsilon of the Mycobacterium tuberculosis F1Fo ATP synthase and a novel model for mechanism of action of the tuberculosis drug TMC207. Antimicrob. Agents Chemother., 2013, 57(1), 168-176.
[http://dx.doi.org/10.1128/AAC.01039-12] [PMID: 23089752]

Sarathy, J.P.; Gruber, G.; Dick, T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline. Antibiotics (Basel), 2019, 8(4), 261.
[http://dx.doi.org/10.3390/antibiotics8040261] [PMID: 31835707]

Singh, H.; Natt, N.K.; Garewal, N.; Pugazhenthan, T. Bedaquiline: A new weapon against MDR and XDR-TB. Int. J. Basic Clin. Pharmacol., 2013, 2(2), 96-102.
[http://dx.doi.org/10.5455/2319-2003.ijbcp20130301]

Haagsma, A.C.; Podasca, I.; Koul, A.; Andries, K.; Guillemont, J.; Lill, H.; Bald, D. Probing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthase. PLoS One, 2011, 6(8), e23575.
[http://dx.doi.org/10.1371/journal.pone.0023575] [PMID: 21858172]

Dooley, K.E.; Park, J.G.; Swindells, S.; Allen, R.; Haas, D.W.; Cramer, Y.; Aweeka, F.; Wiggins, I.; Gupta, A.; Lizak, P.; Qasba, S. Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267. J. Acquir. Immune Defic. Syndr., 1999, 59(5), 455.

Diacon, A.H.; Donald, P.R.; Pym, A.; Grobusch, M.; Patientia, R.F.; Mahanyele, R.; Bantubani, N.; Narasimooloo, R.; De Marez, T.; van Heeswijk, R.; Lounis, N.; Meyvisch, P.; Andries, K.; McNeeley, D.F. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob. Agents Chemother., 2012, 56(6), 3271-3276.
[http://dx.doi.org/10.1128/AAC.06126-11] [PMID: 22391540]

Mesens, N.; Steemans, M.; Hansen, E.; Verheyen, G.R.; Van Goethem, F.; Van Gompel, J. Screening for phospholipidosis induced by central nervous drugs: Comparing the predictivity of an in-vitro assay to high throughput in silico assays. Toxicol. In Vitro, 2010, 24(5), 1417-1425.
[http://dx.doi.org/10.1016/j.tiv.2010.04.007] [PMID: 20430096]

Akkerman, O.W.; Odish, O.F.; Bolhuis, M.S.; de Lange, W.C.; Kremer, H.P.; Luijckx, G.J.; van der Werf, T.S.; Alffenaar, J.W. Pharmacokinetics of bedaquiline in cerebrospinal fluid and serum in multidrug-resistant tuberculous meningitis. Clin. Infect. Dis., 2016, 62(4), 523-524.
[PMID: 26534926]

Kwon, Y.S.; Koh, W.J. Synthetic investigational new drugs for the treatment of tuberculosis. Expert Opin. Investig. Drugs, 2016, 25(2), 183-193.
[http://dx.doi.org/10.1517/13543784.2016.1121993] [PMID: 26576631]

De Matteis, L.; Jary, D.; Lucía, A.; García-Embid, S.; Serrano-Sevilla, I.; Pérez, D.; Ainsa, J.A.; Navarro, F.P.; De la Fuente, J.M. New active formulations against M. tuberculosis: Bedaquiline encapsulation in lipid nanoparticles and chitosan nanocapsules. Chem. Eng. J., 2018, 340, 181-191.
[http://dx.doi.org/10.1016/j.cej.2017.12.110]

Rawal, T.; Patel, S.; Butani, S. Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline. Eur. J. Pharm. Sci., 2018, 124, 273-287.
[http://dx.doi.org/10.1016/j.ejps.2018.08.038] [PMID: 30176365]

Pamreddy, A.; Baijnath, S.; Naicker, T.; Ntshangase, S.; Mdanda, S.; Lubanyana, H.; Kruger, H.G.; Govender, T. Bedaquiline has potential for targeting tuberculosis reservoirs in the central nervous system. RSC Advances, 2018, 8(22), 11902-11907.
[http://dx.doi.org/10.1039/C8RA00984H]

Kaushik, A.; Ammerman, N.C.; Tyagi, S.; Saini, V.; Vervoort, I.; Lachau-Durand, S.; Nuermberger, E.; Andries, K. Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection. Antimicrob. Agents Chemother., 2019, 63(4), e00007-e00019.
[http://dx.doi.org/10.1128/AAC.00007-19] [PMID: 30745396]

Poh, W.; Ab Rahman, N.; Ostrovski, Y.; Sznitman, J.; Pethe, K.; Loo, S.C.J. Active pulmonary targeting against tuberculosis (TB) via triple-encapsulation of Q203, bedaquiline and superparamagnetic iron oxides (SPIOs) in nanoparticle aggregates. Drug Deliv., 2019, 26(1), 1039-1048.
[http://dx.doi.org/10.1080/10717544.2019.1676841] [PMID: 31691600]

Hemelryck, S.V.; Dewulf, J.; Niekus, H.; van Heerden, M.; Ingelse, B.; Holm, R.; Mannaert, E.; Langguth, P. In-vitro evaluation of poloxamer in situ forming gels for bedaquiline fumarate salt and pharmacokinetics following intramuscular injection in rats. Int. J. Pharm. X, 2019, 1, 100016.
[http://dx.doi.org/10.1016/j.ijpx.2019.100016] [PMID: 31517281]

Soria-Carrera, H.; Lucía, A.; De Matteis, L.; Aínsa, J.A.; de la Fuente, J.M.; Martín-Rapún, R. Polypeptidic micelles stabilized with sodium alginate enhance the activity of encapsulated bedaquiline. Macromol. Biosci., 2019, 19(4), e1800397.
[http://dx.doi.org/10.1002/mabi.201800397] [PMID: 30645022]

Momin, M.A.M.; Rangnekar, B.; Sinha, S.; Cheung, C.Y.; Cook, G.M.; Das, S.C. Inhalable dry powder of bedaquiline for pulmonary tuberculosis: In-vitro physicochemical characterization, antimicrobial activity and safety studies. Pharmaceutics, 2019, 11(10), 502.
[http://dx.doi.org/10.3390/pharmaceutics11100502] [PMID: 31581469]

Diacon, A.H.; Pym, A.; Grobusch, M.P.; de los Rios, J.M.; Gotuzzo, E.; Vasilyeva, I.; Leimane, V.; Andries, K.; Bakare, N.; De Marez, T.; Haxaire-Theeuwes, M.; Lounis, N.; Meyvisch, P.; De Paepe, E.; van Heeswijk, R.P.; Dannemann, B. TMC207-C208 Study Group. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N. Engl. J. Med., 2014, 371(8), 723-732.
[http://dx.doi.org/10.1056/NEJMoa1313865] [PMID: 25140958]

Borisov, S.E.; Dheda, K.; Enwerem, M.; Romero Leyet, R.; D’Ambrosio, L.; Centis, R.; Sotgiu, G.; Tiberi, S.; Alffenaar, J.W.; Maryandyshev, A.; Belilovski, E.; Ganatra, S.; Skrahina, A.; Akkerman, O.; Aleksa, A.; Amale, R.; Artsukevich, J.; Bruchfeld, J.; Caminero, J.A.; Carpena Martinez, I.; Codecasa, L.; Dalcolmo, M.; Denholm, J.; Douglas, P.; Duarte, R.; Esmail, A.; Fadul, M.; Filippov, A.; Davies Forsman, L.; Gaga, M.; Garcia-Fuertes, J.A.; García-García, J.M.; Gualano, G.; Jonsson, J.; Kunst, H.; Lau, J.S.; Lazaro Mastrapa, B.; Teran Troya, J.L.; Manga, S.; Manika, K.; González Montaner, P.; Mullerpattan, J.; Oelofse, S.; Ortelli, M.; Palmero, D.J.; Palmieri, F.; Papalia, A.; Papavasileiou, A.; Payen, M.C.; Pontali, E.; Robalo Cordeiro, C.; Saderi, L.; Sadutshang, T.D.; Sanukevich, T.; Solodovnikova, V.; Spanevello, A.; Topgyal, S.; Toscanini, F.; Tramontana, A.R.; Udwadia, Z.F.; Viggiani, P.; White, V.; Zumla, A.; Migliori, G.B. Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: A multicentre study. Eur. Respir. J., 2017, 49(5), 1700387.
[http://dx.doi.org/10.1183/13993003.00387-2017] [PMID: 28529205]

Guglielmetti, L.; Jaspard, M.; Le Dû, D.; Lachâtre, M.; Marigot-Outtandy, D.; Bernard, C.; Veziris, N.; Robert, J.; Yazdanpanah, Y.; Caumes, E.; Fréchet-Jachym, M. French MDR-TB Management Group.Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis. Eur. Respir. J., 2017, 49(3), 1601799.
[http://dx.doi.org/10.1183/13993003.01799-2016] [PMID: 28182570]

Mbuagbaw, L.; Guglielmetti, L.; Hewison, C.; Bakare, N.; Bastard, M.; Caumes, E.; Fréchet-Jachym, M.; Robert, J.; Veziris, N.; Khachatryan, N.; Kotrikadze, T.; Hayrapetyan, A.; Avaliani, Z.; Schünemann, H.J.; Lienhardt, C. Outcomes of bedaquiline treatment in patients with multidrug-resistant tuberculosis. Emerg. Infect. Dis., 2019, 25(5), 936-943.
[http://dx.doi.org/10.3201/eid2505.181823] [PMID: 31002070]

Pym, A.S.; Diacon, A.H.; Tang, S.J.; Conradie, F.; Danilovits, M.; Chuchottaworn, C.; Vasilyeva, I.; Andries, K.; Bakare, N.; De Marez, T.; Haxaire-Theeuwes, M.; Lounis, N.; Meyvisch, P.; Van Baelen, B.; van Heeswijk, R.P.; Dannemann, B. TMC207-C209 Study Group. Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis. Eur. Respir. J., 2016, 47(2), 564-574.
[http://dx.doi.org/10.1183/13993003.00724-2015] [PMID: 26647431]

Gao, M.; Gao, J.; Xie, L.; Wu, G.; Chen, W.; Chen, Y.; Pei, Y.; Li, G.; Liu, Y.; Shu, W.; Fan, L.; Wu, Q.; Du, J.; Chen, X.; Tang, P.; Xiong, Y.; Li, M.; Cai, Q.; Jin, L.; Mei, Z.; Pang, Y.; Li, L. Early outcome and safety of bedaquiline-containing regimens for treatment of MDR- and XDR-TB in China: A multicentre study. Clin. Microbiol. Infect., 2021, 27(4), 597-602.
[http://dx.doi.org/10.1016/j.cmi.2020.06.004] [PMID: 32553880]

Koirala, S.; Borisov, S.; Danila, E.; Mariandyshev, A.; Shrestha, B.; Lukhele, N.; Dalcolmo, M.; Shakya, S.R.; Miliauskas, S.; Kuksa, L.; Manga, S.; Aleksa, A.; Denholm, J.T.; Khadka, H.B.; Skrahina, A.; Diktanas, S.; Ferrarese, M.; Bruchfeld, J.; Koleva, A.; Piubello, A.; Koirala, G.S.; Udwadia, Z.F.; Palmero, D.J.; Munoz-Torrico, M.; Gc, R.; Gualano, G.; Grecu, V.I.; Motta, I.; Papavasileiou, A.; Li, Y.; Hoefsloot, W.; Kunst, H.; Mazza-Stalder, J.; Payen, M.C.; Akkerman, O.W.; Bernal, E.; Manfrin, V.; Matteelli, A.; Mustafa Hamdan, H.; Nieto Marcos, M.; Cadiñanos Loidi, J.; Cebrian Gallardo, J.J.; Duarte, R.; Escobar Salinas, N.; Gomez Rosso, R.; Laniado-Laborín, R.; Martínez Robles, E.; Quirós Fernandez, S.; Rendon, A.; Solovic, I.; Tadolini, M.; Viggiani, P.; Belilovski, E.; Boeree, M.J.; Cai, Q. Davidavičienė E.; Forsman, L.D.; De Los Rios, J.; Drakšienė J.; Duga, A.; Elamin, S.E.; Filippov, A.; Garcia, A.; Gaudiesiute, I.; Gavazova, B.; Gayoso, R.; Gruslys, V.; Jonsson, J.; Khimova, E.; Madonsela, G.; Magis-Escurra, C.; Marchese, V.; Matei, M.; Moschos, C.; Nakčerienė B.; Nicod, L.; Palmieri, F.; Pontarelli, A.; Šmite, A.; Souleymane, M.B.; Vescovo, M.; Zablockis, R.; Zhurkin, D.; Alffenaar, J.W.; Caminero, J.A.; Codecasa, L.R.; García-García, J.M.; Esposito, S.; Saderi, L.; Spanevello, A.; Visca, D.; Tiberi, S.; Pontali, E.; Centis, R.; D’Ambrosio, L.; van den Boom, M.; Sotgiu, G.; Migliori, G.B. Outcome of treatment of MDR-TB or drug-resistant patients treated with bedaquiline and delamanid: Results from a large global cohort. Pulmonology, 2021, 27(5), 403-412.
[http://dx.doi.org/10.1016/j.pulmoe.2021.02.006] [PMID: 33753021]

Ndjeka, N.; Schnippel, K.; Master, I.; Meintjes, G.; Maartens, G.; Romero, R.; Padanilam, X.; Enwerem, M.; Chotoo, S.; Singh, N.; Hughes, J.; Variava, E.; Ferreira, H.; Te Riele, J.; Ismail, N.; Mohr, E.; Bantubani, N.; Conradie, F. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen. Eur. Respir. J., 2018, 52(6), 1801528.
[http://dx.doi.org/10.1183/13993003.01528-2018] [PMID: 30361246]

Franke, M.F.; Khan, P.; Hewison, C.; Khan, U.; Huerga, H.; Seung, K.J.; Rich, M.L.; Zarli, K.; Samieva, N.; Oyewusi, L.; Nair, P.; Mudassar, M.; Melikyan, N.; Lenggogeni, P.; Lecca, L.; Kumsa, A.; Khan, M.; Islam, S.; Hussein, K.; Docteur, W.; Chumburidze, N.; Berikova, E.; Atshemyan, H.; Atwood, S.; Alam, M.; Ahmed, S.; Bastard, M.; Mitnick, C.D. Culture conversion in patients treated with bedaquiline and/or delamanid. a prospective multicountry study. Am. J. Respir. Crit. Care Med., 2021, 203(1), 111-119.
[http://dx.doi.org/10.1164/rccm.202001-0135OC] [PMID: 32706644]

Kang, H.; Jo, K.W.; Jeon, D.; Yim, J.J.; Shim, T.S. Interim treatment outcomes in multidrug-resistant tuberculosis using bedaquiline and/or delamanid in South Korea. Respir. Med., 2020, 167, 105956.
[http://dx.doi.org/10.1016/j.rmed.2020.105956] [PMID: 32421540]

Dooley, K.E.; Nuermberger, E.L.; Diacon, A.H. Pipeline of drugs for related diseases: Tuberculosis. Curr. Opin. HIV AIDS, 2013, 8(6), 579-585.
[http://dx.doi.org/10.1097/COH.0000000000000009] [PMID: 24100880]

Sharma, S.; Singh, A. Phenothiazines as anti-tubercular agents: Mechanistic insights and clinical implications. Expert Opin. Investig. Drugs, 2011, 20(12), 1665-1676.
[http://dx.doi.org/10.1517/13543784.2011.628657] [PMID: 22014039]

Kristiansen, J.E.; Dastidar, S.G.; Palchoudhuri, S.; Roy, D.S.; Das, S.; Hendricks, O.; Christensen, J.B. Phenothiazines as a solution for multidrug resistant tuberculosis: From the origin to present. Int. Microbiol., 2015, 18(1), 1-12.
[PMID: 26415662]

Rodrigues, L.; Cravo, P.; Viveiros, M. Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: A new strategy to revisit mycobacterial targets and repurpose old drugs. Expert Rev. Anti Infect. Ther., 2020, 18(8), 741-757.
[http://dx.doi.org/10.1080/14787210.2020.1760845] [PMID: 32434397]

Gupta, S.; Cohen, K.A.; Winglee, K.; Maiga, M.; Diarra, B.; Bishai, W.R. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2014, 58(1), 574-576.
[http://dx.doi.org/10.1128/AAC.01462-13] [PMID: 24126586]

Reichlen, M.J.; Leistikow, R.L.; Scobey, M.S.; Born, S.E.M.; Voskuil, M.I. Anaerobic Mycobacterium tuberculosis cell death stems from intracellular acidification mitigated by the DosR regulon. J. Bacteriol., 2017, 199(23), e00320-e17.
[http://dx.doi.org/10.1128/JB.00320-17] [PMID: 28874407]

Pasca, M.R.; Guglierame, P.; Arcesi, F.; Bellinzoni, M.; De Rossi, E.; Riccardi, G. Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2004, 48(8), 3175-3178.
[http://dx.doi.org/10.1128/AAC.48.8.3175-3178.2004] [PMID: 15273144]

Lechartier, B.; Cole, S.T. Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 2015, 59(8), 4457-4463.
[http://dx.doi.org/10.1128/AAC.00395-15] [PMID: 25987624]

Yew, W.W.; Lee, J. Drug treatment of chronic tuberculous empyema. Chest, 1992, 101(6), 1741-1742.
[http://dx.doi.org/10.1378/chest.101.6.1741-b] [PMID: 1600813]

Temple, M.E.; Nahata, M.C. Rifapentine: Its role in the treatment of tuberculosis. Ann. Pharmacother., 1999, 33(11), 1203-1210.
[http://dx.doi.org/10.1345/aph.18450] [PMID: 10573321]

Zheng, C.; Hu, X.; Zhao, L.; Hu, M.; Gao, F. Clinical and pharmacological hallmarks of rifapentine’s use in diabetes patients with active and latent tuberculosis: Do we know enough? Drug Des. Devel. Ther., 2017, 11, 2957-2968.
[http://dx.doi.org/10.2147/DDDT.S146506] [PMID: 29066867]